Clearmind Medicine (CMND) announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind’s US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines. Prior to joining Clearmind, Gifford served as Chief of Global Impact at Psyence BioMed (PBM).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Clearmind enrolls last patient in first cohort of CMND-100 trial
- Clearmind Medicine enrolls last patient for first cohort of CMND-100 trial
- SciSparc, Clearmind announce publication of U.S. patent application
- Clearmind announces publication of U.S. patent application on binge behavior
- Psychedelic: Exclusive talk with ibogaine clinic Beond